CareCost Vials
4 × 500 mg
1 billing unit = 10 mg
1,600 mg dose → 160 billing units
J3241 · teprotumumab-trbw
500 mg single-dose vial · most weights carry a JW line
Calculate this patient's units ↓Typical Tepezza dose: 20 mg/kg (10 mg/kg for the first infusion)
This Tepezza claim carries straight into Claim Check.
Claim Check builds the whole visit — J3241 units, the administration line, the modifiers and the Medicare allowed amount — and prices it against your payer's rate. The estimate turns the same visit into what the patient owes.
Free · No credit card · No sales call
Patient owes, 1,600 mg
Change the payer and the estimate re-prices against that payer's own published rate. The result is a good faith estimate for the patient.
37 payer price files · Commercial + Medicare · Copay and foundation status · Deductible, coinsurance and out-of-pocket math
Tepezza J3241 is billed in units of 10 mg: weight (kg) × dose (mg/kg) = dose in mg ÷ 10 mg/unit = billing units. A course carries two dose levels: 10 mg/kg for the first infusion, then 20 mg/kg every 3 weeks for seven more. For an 80 kg adult the first infusion is 800 mg ÷ 10 = 80 units; each infusion after it is 1,600 mg ÷ 10 = 160 units.
Tepezza ships in a single 500 mg vial, so the mg drawn can exceed the mg administered whenever a dose is not an exact multiple of 500 mg. Report any leftover as JW; use JZ only when nothing was discarded. At 80 kg, the 800 mg first infusion draws two vials (1,000 mg) with 200 mg left over, and the 1,600 mg dose that follows draws four vials (2,000 mg) with 400 mg left over — real money, as the table below shows.
Medicare pays $381.627 per billing unit for J3241, effective for claims in Q4 2026:
$61,060.32 for the 160-unit continuing-dose example above, plus $15,265.08 on the 40-unit JW line and
$133.27 for the 96413 administration line — $76,458.67 Medicare allowed.
Weight sets both the first infusion and the seven that follow it; the single 500 mg vial decides how much of each draw is discarded.
| Patient | Weight | Dose | Units | Vials drawn | Modifier |
|---|---|---|---|---|---|
| First infusion, 10 mg/kg | 80 kg | 800 mg | 80 | 2 × 500 mg (200 mg discarded) | JW |
| Continuing infusion, 20 mg/kg (default) | 80 kg | 1,600 mg | 160 | 4 × 500 mg (400 mg discarded) | JW |
| Continuing infusion, 20 mg/kg | 100 kg | 2,000 mg | 200 | 4 × 500 mg | JZ |
| Continuing infusion, 20 mg/kg | 70 kg | 1,400 mg | 140 | 3 × 500 mg (100 mg discarded) | JW |
The label sets no dose cap, so the calculator multiplies the ordered mg/kg through at any weight; the J3241 MUE is 500 units (5,000 mg) a day, well above a single infusion at these weights. Only the 100 kg row draws exactly four full vials with nothing left over. Every other row discards a remainder onto its own JW line, as the next section works through, and each row is one claim of the eight that make up a course.
JZ — no discarded drug from a single-dose container. JW — discarded drug from a single-dose container, reported on its own claim line.
J3241 × 160 · J3241 × 40 JW · 96413 × 1.
The administered line carries no modifier when a JW line is reported.
J3241 × 200 JZ · 96413 × 1.
96413 covers the initial hour of a chemotherapy or complex-biologic infusion. The label runs the first two Tepezza infusions over at least 90 minutes and every infusion after that over at least 60 minutes if the first two were well tolerated (90 minutes if not), so an infusion that stops at the label minimum bills 96413 alone. 96415 (each additional hour) is added only when a first or second infusion actually runs past 90 minutes; a payer that places teprotumumab in its therapeutic-infusion family instead of the complex-biologic family wants 96365, and 96366 past 90 minutes.
The label sets no dose cap, so the units line has no cap of its own, but the J3241 MUE is 500 units (5,000 mg) a day.
Eight infusions make up one course — the first at 10 mg/kg, then seven at 20 mg/kg every 3 weeks — and the corpus treats a course as once per lifetime, so each infusion is billed on its own claim, eight claims per course. There is no subcutaneous Tepezza.
Tepezza IV ships as a lyophilized powder in a single 500 mg single-dose vial (NDC 75987-130-15). Each vial is reconstituted with 10 mL of sterile water to a 47.6 mg/mL concentration, then diluted into a 100 mL bag of 0.9% sodium chloride for doses under 1,800 mg, or a 250 mL bag for doses of 1,800 mg and over, before the infusion.
Every dose is drawn from the same 500 mg vial and billed under J3241; there is no subcutaneous product. See the FDA Tepezza label (BLA761143) for the full reconstitution and administration instructions.
J3241 is the HCPCS code for reference Tepezza (teprotumumab-trbw) administered intravenously. No teprotumumab-trbw biosimilar exists, and there is no same-class alternative billed under its own J-code. See the HCPCS hub for coding across the full family. The Medicare rate for every quarter is on the cost page →
80 billing units administered. Tepezza's first infusion is 10 mg/kg: 80 kg × 10 mg/kg = 800 mg ÷ 10 = 80 units, drawn from two 500 mg vials (1,000 mg) with 200 mg (20 units) left over on a JW line.
160 billing units administered. From the second infusion on, Tepezza is dosed at 20 mg/kg: 80 kg × 20 mg/kg = 1,600 mg ÷ 10 = 160 units, drawn from four 500 mg vials (2,000 mg) with 400 mg (40 units) left over on a JW line — $15,265.08 of drug at the Q4 2026 rate of $381.627 per unit.
Both, depending on the weight. Tepezza's only vial is 500 mg, so most weights leave a remainder that has to be reported on a JW line; a weight whose dose divides evenly into 500 mg, such as 100 kg at 2,000 mg, draws exactly four vials and bills JZ instead. The administered line never carries a modifier when a JW line is also reported.
96413 alone, for an infusion that stops at the label minimum. The first two infusions run at least 90 minutes and later ones at least 60 minutes if well tolerated; 96415 (each additional hour) is added only when a first or second infusion actually runs past 90 minutes. A payer that places teprotumumab in its therapeutic-infusion family instead wants 96365, and 96366 past 90 minutes.
Eight: the first at 10 mg/kg, then seven at 20 mg/kg every 3 weeks, about 21 weeks from first to last. The label describes one course, and the corpus treats it as once per lifetime, so each infusion is billed on its own claim — eight claims for the course.
$381.627 per billing unit (per 10 mg), effective for claims in Q4 2026: $61,060.32 for the 160-unit continuing-dose example above, plus $15,265.08 on the 40-unit JW line and $133.27 for the 96413 administration line — $76,458.67 Medicare allowed.
Data current: pricing Q4 2026 · payer policies Aug 2026
Sources: CMS ASP pricing files (Q4 2026); FDA-approved prescribing information (TEPEZZA label, revised July 2026, BLA761143); CMS single-dose container JW/JZ policy (effective July 1, 2023); 28 commercial payer medical policies (Clearance corpus); CPT codebook administration-code guidance.
Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →